The Impact of Cancer-Related Fatigue on HRQOL in Survivors of Childhood Cancer: A DCCSS LATER Study.
cancer survivorship
fatigue
health-related quality of life
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Jun 2022
09 Jun 2022
Historique:
received:
02
05
2022
revised:
31
05
2022
accepted:
03
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Early detection and management of late effects of treatment and their impact on health-related quality of life (HRQOL) has become a key goal of childhood cancer survivorship care. One of the most prevalent late effects is chronic fatigue (CF). The current study aimed to investigate the association between CF and HRQOL in a nationwide cohort of CCS. Participants were included from the Dutch Childhood Cancer Survivor Study (DCCSS) LATER cohort, a nationwide cohort of CCS. Participants completed the Checklist Individual Strength (CIS) to indicate CF (CIS fatigue severity subscale ≥ 35 and duration of symptoms ≥6 months) and the Short Form-36 (SF-36) and TNO (Netherlands Organization for Applied Scientific Research) and AZL (Leiden University Medical Centre) Adult's Health-Related Quality of Life questionnaire (TAAQOL) as measures for HRQOL. Differences in mean HRQOL domain scores between CF and non-CF participants were investigated using independent samples A total of 1695 participants were included in the study. Mean HRQOL domain scores were significantly lower in participants with CF. In addition, CF was associated with impaired HRQOL on all of the domains (except physical functioning) with adjusted odds ratios ranging from 2.1 (95% CI 1.3-3.4; sexuality domain) to 30.4 (95% CI 16.4-56.2; vitality domain). CF is associated with impaired HRQOL, urging for the screening and regular monitoring of fatigue, and developing possible preventative programs and interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Early detection and management of late effects of treatment and their impact on health-related quality of life (HRQOL) has become a key goal of childhood cancer survivorship care. One of the most prevalent late effects is chronic fatigue (CF). The current study aimed to investigate the association between CF and HRQOL in a nationwide cohort of CCS.
METHODS
METHODS
Participants were included from the Dutch Childhood Cancer Survivor Study (DCCSS) LATER cohort, a nationwide cohort of CCS. Participants completed the Checklist Individual Strength (CIS) to indicate CF (CIS fatigue severity subscale ≥ 35 and duration of symptoms ≥6 months) and the Short Form-36 (SF-36) and TNO (Netherlands Organization for Applied Scientific Research) and AZL (Leiden University Medical Centre) Adult's Health-Related Quality of Life questionnaire (TAAQOL) as measures for HRQOL. Differences in mean HRQOL domain scores between CF and non-CF participants were investigated using independent samples
RESULTS
RESULTS
A total of 1695 participants were included in the study. Mean HRQOL domain scores were significantly lower in participants with CF. In addition, CF was associated with impaired HRQOL on all of the domains (except physical functioning) with adjusted odds ratios ranging from 2.1 (95% CI 1.3-3.4; sexuality domain) to 30.4 (95% CI 16.4-56.2; vitality domain).
CONCLUSIONS
CONCLUSIONS
CF is associated with impaired HRQOL, urging for the screening and regular monitoring of fatigue, and developing possible preventative programs and interventions.
Identifiants
pubmed: 35740518
pii: cancers14122851
doi: 10.3390/cancers14122851
pmc: PMC9221067
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Dutch Cancer Society
ID : KUN 2014-6985
Organisme : 'stichting Kinderen Kankervrij' (KIKA)&ODAS
ID : 171 'DCOG LATER
Références
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Qual Life Res. 2004 May;13(4):735-45
pubmed: 15129884
BMC Med Res Methodol. 2009 Jul 28;9:57
pubmed: 19638200
Eur J Cancer. 2021 Jul;152:204-214
pubmed: 34119924
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
Mov Disord. 2018 Nov;33(11):1712-1723
pubmed: 30264539
Pediatr Blood Cancer. 2007 Sep;49(3):298-305
pubmed: 16779805
Sleep. 2008 Feb;31(2):271-81
pubmed: 18274275
Curr Rheumatol Rep. 2017 May;19(5):25
pubmed: 28386762
Support Care Cancer. 2022 Jan;30(1):359-366
pubmed: 34287690
J Cancer Surviv. 2015 Dec;9(4):620-9
pubmed: 25708515
Chron World Health Organ. 1947;1(1-2):29-43
pubmed: 20267861
J Psychosom Res. 2020 Aug 28;137:110229
pubmed: 32890861
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):435-46
pubmed: 18268128
J Clin Oncol. 2017 Jul 10;35(20):2288-2298
pubmed: 28530852
J Adolesc Young Adult Oncol. 2021 Feb;10(1):92-99
pubmed: 32857640
Int J Hematol. 2010 Jul;92(1):95-104
pubmed: 20577841
Pediatr Blood Cancer. 2012 Mar;58(3):415-20
pubmed: 21425447
Int J Integr Care. 2018 Jan 16;18(1):4
pubmed: 29588641
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Cancer. 2022 Mar 01;128(5):1074-1084
pubmed: 34726782
Support Care Cancer. 2016 Sep;24(9):3951-9
pubmed: 27117558
Ann Oncol. 2007 Nov;18(11):1898-902
pubmed: 17804470
Surg Oncol Clin N Am. 2018 Oct;27(4):675-684
pubmed: 30213412
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Soc Sci Med. 1995 Nov;41(10):1403-9
pubmed: 8560308
Ned Tijdschr Geneeskd. 1997 Aug 2;141(31):1526-30
pubmed: 9543741
J Cancer Surviv. 2020 Oct;14(5):666-676
pubmed: 32363495
Cancer Med. 2022 Feb;11(4):1172-1180
pubmed: 34953059
Cancer. 2022 Mar 1;128(5):1110-1121
pubmed: 34724201
J Cancer Surviv. 2020 Dec;14(6):923-938
pubmed: 32839902
J Pediatr Hematol Oncol. 2019 May;41(4):313-318
pubmed: 30475298
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Int J Sports Med. 2020 Oct;41(11):790-797
pubmed: 32599641
Dialogues Clin Neurosci. 2014 Jun;16(2):137-45
pubmed: 25152653
J Psychosom Res. 1994 Jul;38(5):383-92
pubmed: 7965927
J Psychosom Res. 2017 Jul;98:40-46
pubmed: 28554371
Cancer. 2021 Sep 15;127(18):3445-3456
pubmed: 34043810
Sci Rep. 2021 Nov 12;11(1):22153
pubmed: 34773047
Aliment Pharmacol Ther. 2011 Jan;33(1):106-14
pubmed: 21083587
BMC Med Res Methodol. 2021 May 16;21(1):106
pubmed: 33993873
Leukemia. 2019 Jun;33(6):1349-1359
pubmed: 30568171
J Occup Environ Med. 2014 Jul;56(7):686-98
pubmed: 24988095
J Clin Oncol. 2014 Jun 10;32(17):1840-50
pubmed: 24733803
J Clin Epidemiol. 2006 Oct;59(10):1087-91
pubmed: 16980149
Cochrane Database Syst Rev. 2020 Mar 3;3:CD012681
pubmed: 32124971